Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
RESEARCH TOOLSreports
DBV Technologies SA - American (DBVT) Stock Price & Analysis
347 Followers
DBVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.65 - $2.37
Previous Close$0.67
Volume28.96K
Average Volume (3M)52.68K
Market Cap
$124.04M
Enterprise Value-$11.65M
Total Cash (Recent Filing)$141.37M
Total Debt (Recent Filing)$5.67M
Price to Earnings (P/E)-1.7
Beta0.08
Next Earnings
Jul 29, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding192,863,540
10 Day Avg. Volume31,684
30 Day Avg. Volume52,680
Standard Deviation0.27
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.92
Price to Sales (P/S)8.18
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.74
Enterprise Value/Gross Profit-0.74
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$7.00Price Target Upside949.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
DBV Technologies SA - American News
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressAnticipated trial initiation for Viaskin in different age groups demonstrates progress in the company's development pipeline.
Safety And Efficacy DataPositive interim safety and efficacy data from the EPITOPE trial in toddlers support the continued development of Viaskin.
Stock RecommendationAnalyst reiterates a Buy rating and maintains a $10 price target for Viaskin, reflecting confidence in the stock's potential.
Bears Say
Financial Performance4Q23 Operating Expenses of $24M were slightly above the estimate of $21M, resulting in a net loss of $14M.
Market AdoptionXolair’s black box warning for anaphylaxis and steep price might limit its adoption.
Regulatory ChallengesXolair's recent FDA approval with black box warning—food allergy context presents a particular challenge for patient adoption, especially for repeated injections in young children.
---
Ownership Overview
15.23% Insiders
0.28% Mutual Funds
1.48% Other Institutional Investors
83.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $0.65 and its highest was $2.37 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
Currently, no data Available
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is Jul 29, 2024 which is in 85 days.
How were DBV Technologies SA - American’s earnings last quarter?
Currently, no data Available
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 192,868,740 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Among the largest hedge funds holding DBV Technologies SA - American’s share is Baker Bros Advisors LP. It holds DBV Technologies SA - American’s shares valued at 14M.
---
DBV Technologies SA - American Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (949.63% Upside)
$7.00 (949.63% Upside)
Hedge Fund Trend
Decreased
By 6.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.30%
12-Months-Change
Fundamentals
Return on Equity
-43.47%
Trailing 12-Months
Asset Growth
-25.77%
Trailing 12-Months
Company Description
DBV Technologies SA - American
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
---
DBVT Earnings Call
Q4 2024
0:00 / 0:00
---
DBVT Stock 12 Months Forecast
Average Price Target
$7.00
▲(949.63% Upside)
Technical Analysis
Best Analysts Covering DBVT
1 Year
1 Year Success Rate
5/20 ratings generated profit
1 Year Average Return
-22.67%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -22.67% per trade.
---